Insights
Insights From Our Experts
Articles
U.S. Drug Pricing Is Entering a More Complex Phase
The U.S. drug pricing landscape is undergoing a fundamental transformation. Historically insulated from international reference pricing, new policy developments, such as the emergence of TrumpRx and Most Favored Nation (MFN) dynamics, are dismantling traditional benchmarks. Instead of relying on a single,…
Bridging Evidence Gaps in mCRPC: Highlighting the Potential of Talazoparib plus Enzalutamide
Innovation in oncology is accelerating, but the evidence needed to guide treatment decision-making often lags behind. This is particularly evident in metastatic castration-resistant prostate cancer (mCRPC). In mCRPC, multiple PARP inhibitors combined with androgen receptor pathway…
Decoding the Dialogue: Transforming MSL Interactions into Congress Intelligence
Oncology innovation is accelerating, but the ability to turn congress interactions into timely, actionable insights remains a challenge. High volumes of unstructured MSL and HCP data often slow analysis, limit visibility and delay strategic action. This…
The Shattered Glass: Why the Future of Oncology Patient Support is an Agentic Ecosystem, Not a Portal
Oncology innovation is accelerating, but the systems supporting it are falling behind – creating administrative friction, fragmented workflows, and delays in care. This challenge is the focus of our new thought leadership series, beginning with this…
Your Market Access Model is Bleeding Value
Your market access model may be quietly eroding more value than you realize. In today’s environment, up to 50% of commercial value is lost due to market access challenges. As policy pressures from the IRA, evolving…
Can Direct‑to‑Employer Models Redefine Access to Obesity Care?
As demand for GLP‑1 therapies continues to rise, employers are facing increasing pressure to balance affordability, access, and outcomes. What was once a benefits challenge has quickly become a core strategic issue — influencing talent retention,…
Views from Asembia: What Pharma Leaders Are Prioritizing Now
Insights from Krista Pinto on access, AI, and the shift to integrated commercialization Following Asembia 2026, a clear picture is emerging of what matters most to pharmaceutical leaders today. In a recent interview with pharmaphorum, Krista Pinto, a commercialization expert at EVERSANA,…
How MFN is Reshaping Global Drug Pricing – and How NAVLIN Insights Tracks It
Nearly a year after the executive order to implement Most Favored Nation (MFN) drug pricing policy in the U.S., clear strategic pictures are emerging, including: Launch prices in Europe that are higher than launch prices in the U.S. Prices in Japan that are 90-100% lower than the U.S. Longer launch timelines outside…
How Pharma Can Scale Innovation Without Losing Executional Rigor
As the commercialization landscape grows more complex, pharmaceutical manufacturers are being challenged to scale innovation while maintaining executional rigor. Rising expectations around access, data integration, and AI adoption are forcing organizations to rethink how they operate across the product lifecycle. …
Predicting PICOs Under EU Joint Clinical Assessment: Is One Method Enough?
The European Union’s new Joint Clinical Assessment (JCA) framework is set to revolutionize market access, but it also introduces a new layer of complexity. With a single clinical assessment informing reimbursement decisions across all member states, the stakes…